Aardvark (AARD) Form 144 Shows Proposed Sale and Recent Fund Dispositions
Rhea-AI Filing Summary
Aardvark Therapeutics (AARD) filed a Form 144 to notify a proposed sale of 10,360 common shares by an affiliate through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $93,413.01 and an approximate sale date of 09/15/2025. The filing shows these shares were acquired from the issuer in a private transaction on 05/16/2019 for cash. The company reports 21,696,893 shares outstanding, which provides context for the size of the proposed sale relative to the float.
The filing also discloses recent sales by VICKERS VENT GLB DEEP-TECH FND I LP of 20,000 shares on 09/02/2025 for gross proceeds of $170,118.00 and 27,691 shares on 08/28/2025 for gross proceeds of $241,565.21. The notice includes the standard signer representation that no undisclosed material adverse information is known to the seller.
Positive
- None.
Negative
- Recent substantial sales disclosed: VICKERS VENT GLB DEEP-TECH FND I LP sold 20,000 shares (09/02/2025) and 27,691 shares (08/28/2025) yielding combined gross proceeds of $411,683.21.
Insights
TL;DR: Affiliate proposes to sell 10,360 shares; prior recent fund sales totaling 47,691 shares were reported.
The filing documents a proposed sale under Rule 144 of 10,360 common shares via Morgan Stanley Smith Barney with an indicated aggregate market value of $93,413.01. The shares were originally acquired in a private issuance on 05/16/2019 and paid in cash. Separately, the filing discloses two prior dispositions by VICKERS VENT GLB DEEP-TECH FND I LP totaling 47,691 shares with combined gross proceeds of $411,683.21. For investors, these are factual disclosure items required by Rule 144; the filing does not include any explanation of motivations or additional covenants.
TL;DR: Routine Rule 144 notice showing affiliate and fund sales; contains seller's certification of no undisclosed material information.
This Form 144 includes the seller's representation that they are unaware of any material adverse information not publicly disclosed. It lists the broker, sale date, and historical acquisition details (private acquisition from the issuer on 05/16/2019). The filing is procedural and informational; it does not itself alter corporate governance or disclose management changes.
FAQ
What does the Form 144 filed for AARD disclose?
Who acquired the shares being sold and when?
How many AARD shares are outstanding according to the filing?
Were there any recent sales of AARD shares disclosed in the filing?
Which broker is named for the proposed sale?